OpenAI seen preparing for 2027 IPO at $1 trln valuation- Reuters
Investing.com -- Guardant Health Inc (NASDAQ:GH) shares surged 16.1% in after-hours trading Wednesday after the precision oncology company reported third-quarter results that significantly exceeded analyst expectations and raised its full-year guidance.
The company reported adjusted earnings per share of -$0.39 for the third quarter, substantially better than the -$0.79 analysts had estimated. Revenue jumped 39% YoY to $265.2 million, well above the consensus estimate of $235.64 million. The strong performance was broadly driven by growth across all business segments.
Guardant’s oncology revenue grew 31% to $184.4 million with test volume increasing 40% YoY. Screening revenue reached $24.1 million with approximately 24,000 Shield screening tests, compared to just $1.0 million in the same period last year. Biopharma and data revenue rose 18% to $54.7 million.
"This was an exceptional quarter for Guardant with broad-based growth across our business," said Helmy Eltoukhy, co-founder and co-CEO. "Notably, this quarter we crossed over $1 billion in annualized revenue."
Following the strong results, Guardant raised its full-year 2025 revenue guidance to $965-$970 million, representing 31% YoY growth and exceeding the analyst consensus of $922 million. The company now expects oncology revenue to grow approximately 25% YoY, up from prior guidance of 20%, and increased its screening revenue forecast to $71-$73 million from $55-$60 million previously.
The company also improved its non-GAAP gross margin to 66% in the quarter, up from 63% in the same period last year, and now expects full-year gross margin of 64-65%, better than its previous forecast of 63-64%.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.